Jenny Freeman

Dr. Jenny Freeman is a board certified cardiothoracic surgeon with long-standing research interests related to the vascular system ranging from the subcellular to the clinical. She brings over 25 years of broad hands-on experience in medicine, scientific investigation and entrepreneurship including clinical and academic cardiothoracic surgery, biomedical research and medical device innovation. This has encompassed the research, development, implementation and evaluation of new devices, pharmaceuticals and health care consumer goods as well as clinical cost and outcomes analyses and the development of new surgical programs.

Dr. Freeman graduated from Yale University with a BA in Molecular Biochemistry and Biophysics, with early work and publications on cyclic nucleotides and co-authorship of the first publication on the regulation of phosphodiesterase in 1973. She then undertook her medical school education and general surgery training at New York University/Bellevue Hospital under Dr. Frank Spencer, finishing her residency in 1984.  Specialized training was also obtained in a variety of areas, including work in the pediatric cardiovascular catheterization laboratory at the Cardiovascular Research Institute at the University of California at San Francisco with Drs. Abe Rudolf and Paul Stanger and a year of pediatric surgery and pediatric cardiovascular surgery at Boston Children’s Hospital with Drs. Judah Folkman and Aldo Castaneda.  Following her general surgical training, she obtained an American Heart Association grant and undertook a two year postdoctoral fellowship in Vascular Biology at the University of Washington in the Department of Pathology laboratories of Drs. Schwartz, Gajduseck and Ross working on PDGF (platelet derived growth factor) and other cellular mediators in animal and cell culture models.

Her surgical experience has included a formal cardiothoracic residency with Dr. John Kirklin at the University of Alabama at Birmingham (which included substantial experience in cardiac transplantation and the fundamentals of biostatistics and evidence based medicine) and a pediatric cardiovascular fellowship at the Children’s Hospital of Philadelphia with Dr. William Norwood. She practiced pediatric cardiovascular surgery for eight years in both academic and private practice settings. In 1996 she left full time practice to pursue research interests in the Division of Visual and Circulatory Biophysics in the Department of Engineering at Boston University.

In 1998 she left the research environment to pursue an entrepreneurial path with the founding of two medical device companies and a Wall Street healthcare research firm. She was the founding CEO of Argose, Inc. which was devoted to the development of a fluorescent spectroscopy system for use in the non-invasive monitoring of glucose in diabetics. There she built the company to 50 employees and raised $17 million in private equity financing. Most recently, Dr. Freeman was the CEO of HyperMed, Inc., which is developing and commercializing medical hyperspectral imaging as a quantitative metric of tissue oxygenation. There she procured over $5M in research grant funding as Principal Investigator from the NIH and other sources and obtained $5M of venture capital financing. She continues to maintain surgical and hospital credentialing and is a member of the Massachusetts General Hospital International Medical and Surgical Response Team. Dr. Freeman now has over 50 peer-reviewed publications and presentations in biochemical, physiology and cardiovascular surgical areas and over 20 issued and pending patents. Since leaving HyperMed in mid 2007, Dr. Freeman is now applying her broad business experience and medical and scientific expertise to a variety of projects in the health care arena.